T
Tvardi Therapeutics, Inc. (TVRD)
NCM – Real vaqt narxi. Valyuta: USD
1.50
-0.86 (-36.44%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
1.88
+0.38 (25.33%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
1.50
-0.86 (-36.44%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
1.88
+0.38 (25.33%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Tvardi Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda sezilarli ehtiyojlari qondirilmagan yallig'lanish va proliferativ kasalliklarni davolash uchun signal transduser va transkriptsiya aktivatori 3 (STAT3) ni maqsad qilib olgan yangi, og'iz orqali qabul qilinadigan, kichik molekulali dorilarni ishlab chiqish bilan shug'ullanadi. Kompaniyaning asosiy mahsulot nomzodlari orasida fibroz bilan bog'liq kasalliklar uchun 1b/2-bosqich klinik rivojlanish bosqichida bo'lgan, dastlab idiopatik o'pka fibroziga (IPF) va gepatotsellyulyar karsinomaga (HCC) qaratilgan TTI-101, hamda 1-bosqich klinik sinov bosqichida bo'lgan og'iz orqali qabul qilinadigan, kichik molekulali STAT3 ingibitori TTI-109 mavjud. Tvardi Therapeutics, Inc. 2017 yilda tashkil etilgan va Sugar Land, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Imran Alibhai Ph.D. | CEO & Director |
| Dr. Jeffrey Larson DABT, Ph.D. | Senior Vice President of R&D |
| Dr. John Kauh M.D. | Chief Medical Officer |
| Dr. Michael T. Lewis Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Ronald A. DePinho M.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Yixin Chen Ph.D. | Vice President of CMC |
| Mr. Dan Conn J.D., M.B.A. | CFO & Corporate Secretary |
| Mr. David J. Tweardy M.D. | Co-Founder & Scientific Advisory Board Member |
| Mr. Stephen O'Brien CPA | VP of Finance & Corporate Controller |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-11 | 8-K | tm2617528d1_8k.htm |
| 2026-05-08 | POS AM | tm269412-2_posam.htm |
| 2026-05-08 | 8-K | tm2613977d1_8k.htm |
| 2026-05-08 | 10-Q | tvrd-20260331x10q.htm |
| 2026-05-01 | S-3 | tm2613101-1_s3.htm |
| 2026-04-23 | DEFA14A | tm266756d2_defa14a.htm |
| 2026-04-23 | ARS | tm266752d2_ars.pdf |
| 2026-04-01 | S-8 | tm2610047d3_s8.htm |
| 2026-04-01 | POS EX | tm2610047d2_posex.htm |
| 2026-03-31 | 8-K | tm2610603d1_8k.htm |